Indivior reported 171M in Operating Expenses for its fiscal semester ending in March of 2026.





Operating Expenses Change Date
AstraZeneca USD 12.22B 4.04B Jun/2026
Cassava Sciences USD 11.17M 2.38M Mar/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Roche Holding CHF 18.9B 2.12B Jun/2026
West Pharmaceutical Services USD 2.99B 200K Jun/2026